AAM
PRVL

Alpine Associates Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Alpine Associates Management’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-857,705
Closed -$19.8M – 63
2020
Q4 		$19.8M Buy
+857,705
New +$10.9M 0.81% 29

Alpine Associates Management's PRVL Position: Q1 2021 in Review

Alpine Associates Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 857,705 shares — an estimated $19.8M sold.

Alpine Associates Management first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $19.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Alpine Associates Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Alpine Associates Management sold 857,705 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $19.8M.
  • Alpine Associates Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Alpine Associates Management's Prevail Therapeutics Inc. Common Stock position peaked at $19.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Alpine Associates Management's 13F filing for Q1 2021, filed 11 May 2021.